Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers; ∼20% of patients have metastases at diagnosis, and 50%-60% subsequently develop metachronous metastases. Bone involvement, despite being rare, is usually associated with higher disease burden, worse prognosis, impaired quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., Santini, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808439/
https://www.ncbi.nlm.nih.gov/pubmed/36327757
http://dx.doi.org/10.1016/j.esmoop.2022.100606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808439/
https://www.ncbi.nlm.nih.gov/pubmed/36327757
http://dx.doi.org/10.1016/j.esmoop.2022.100606

Ejemplares similares